Lantheus’ generic, called 177Lu-PNT2003, was licensed in December 2022 from Point Biopharma, which was acquired by Eli Lilly last month. Lantheus has worldwide rights to the drug, with the ...

Increasing cancer prevalence, including prostate cancer and neuroendocrine tumors, advances in nuclear medicine in the field ...

7 The orphan drug product Lutathera® (lutetium ((177Lu)) oxodotreotide) to treat adults with somatostatin receptor (SSTR) positive gastroentero-pancreatic neuroendocrine tumours (GEP-NETs ...

Objectives The objective is to develop a method to perform simultaneous PET / SPECT imaging on an existing PET scanner. Methods This study was based on a prototype animal PET/CT scanner. The PET ring ...